RxDoctor Payments Data

Marco Felipe Ribeiro

Nurse Practitioner · Middletown, CTNPI 1932616299

Payments from drug & device makers

$1,129in general payments, 2019–2025

Across 73 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$253
  • Lilly USA, LLC$159
  • Boehringer Ingelheim$154
  • AstraZeneca$98
  • Astellas Pharma US Inc$77
  • Otsuka America Pharmaceutical, Inc.$54
  • plus $334 from 14 others

What the payments were for

  • Food & beverage$1,09997%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,129 in reported general payments places this provider in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$45,821
Medicare patients
132
Services billed
575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$51,572
TrulicityDulaglutide50$48,553
FarxigaDapagliflozin Propanediol49$43,880
XareltoRivaroxaban39$40,568
JanuviaSitagliptin Phosphate52$34,330
OzempicSemaglutide16$27,490
RybelsusSemaglutide12$24,401
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$19,714
Spiriva RespimatTiotropium Bromide20$14,103
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$11,634
TrintellixVortioxetine Hydrobromide18$9,756
Bydureon BciseExenatide Microspheres11$8,374
LinzessLinaclotide15$7,571
VascepaIcosapent Ethyl12$4,183
Sumatriptan14$2,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$52$51,89128 claims
PfizerEliquis$35$51,57246 claims
Lilly USA, LLCTrulicity$159$48,55350 claims
AstraZenecaFarxiga$98$43,88049 claims
Johnson & JohnsonXarelto$12$40,56839 claims
MerckJanuvia$48$34,33052 claims
Boehringer IngelheimSpiriva Respimat$154$14,10320 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$30$9,75618 claims
AbbVieLinzess, Synthroid$253$8,29129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →